Arcutis Biotherapeutics, Inc.

Quick facts

Phase 3 pipeline

• ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% · Dermatology
  ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation.
• ARQ-151 cream 0.3% · Dermatology
  ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.
• ARQ-151 vehicle cream · Dermatology
  ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.
• Roflumilast Cream 0.05% · Dermatology
  Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.
• Roflumilast Cream 0.15% · Immunology
  Roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation by blocking the action of phosphodiesterase 4.
• Roflumilast Foam · Dermatology
  Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and inflammatory cells.
• Roflumilast Foam 0.3% · Dermatology
  Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.
• Topical roflumilast · Dermatology
  Topical roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation in the skin.

Phase 2 pipeline

• ARQ-151 cream 0.05% · Dermatology
  ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses.
• ARQ-154 · Dermatology
  ARQ-154 is a topical Janus kinase (JAK) inhibitor.

Phase 1 pipeline

• ARQ-151 cream 0.15% · Dermatology
  ARQ-151 is a selective phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses.
• ARQ-151 cream 0.5%
• ARQ-154 Foam 0.3%
• ARQ-234
• ARQ-252 cream 0.1%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Arcutis Biotherapeutics, Inc. portfolio CI brief
• Arcutis Biotherapeutics, Inc. pipeline updates RSS